ZNF354B Inhibitors
ZNF354B inhibitors collectively target a variety of signaling pathways and molecular mechanisms to achieve a reduction in the functional activity of this transcription factor. Compounds that inhibit kinase activity, such as those affecting the MAPK/ERK and PI3K/AKT pathways, play a pivotal role in the modulation of ZNF354B by altering the phosphorylation states of proteins that could serve as upstream regulators or essential co-factors for ZNF354B. Similarly, inhibitors that act on the stress-activated p38 MAPK and JNK pathways or those that target Akt can change the transcriptional landscape, indirectly leading to the suppression of ZNF354B's role in gene expression. These kinase inhibitors, by intervening in specific signaling cascades, create an environment less conducive to the transactivation potential of ZNF354B. Substances that modulate chromatin structure, such as HDAC inhibitors, also contribute to the regulation of ZNF354B by changing the accessibility of target gene promoters to the transcription factor. This can lead to a downregulation of genes that are normally activated by ZNF354B, further illustrating the complex interplay between epigenetic modifiers and transcription factor activity.
Continuing with the impact on ZNF354B, small molecules that interfere with protein-protein interactions necessary for ZNF354B's recruitment to its DNA binding sites can also effectively diminish its regulatory influence on gene expression. The disruption of these interactions impairs the assembly of transcriptional machinery at the ZNF354B target sites, thus attenuating its function. Furthermore, modulators of cellular signaling, such as calcium channel blockers and inhibitors of G-protein coupled receptors, may also exert downstream effects that limit the ability of ZNF354B to regulate gene transcription.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This kinase inhibitor interacts with protein kinases that phosphorylate ZNF354B, leading to its functional inhibition by preventing the post-translational modifications necessary for its full activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which is upstream in the MAPK/ERK pathway. ZNF354B activity is modulated via this pathway, and inhibition of MEK results in decreased phosphorylation and activation of downstream targets that could affect ZNF354B function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, which plays a role in the PI3K/AKT signaling pathway. This pathway is involved in the regulation of various transcription factors and could indirectly lead to the decreased functional activity of ZNF354B by altering the transcriptional environment in which ZNF354B operates. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor, which modulates the cellular response to stress and inflammatory cytokines. By inhibiting p38 MAPK, this compound indirectly affects the activity of transcription factors and other proteins that interact with ZNF354B, thus leading to its decreased functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which influences transcription factor activity and cell death pathways. Inhibition of JNK can alter transcriptional regulation mechanisms that may be crucial for ZNF354B's role in gene expression, resulting in its functional inhibition. | ||||||
A-443654 | 552325-16-3 | sc-507339 | 1 mg | $140.00 | ||
An Akt inhibitor that indirectly decreases ZNF354B activity by affecting the PI3K/AKT pathway, which is known to regulate various transcription factors and other proteins that could interact with ZNF354B. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor that indirectly leads to decreased ERK phosphorylation, thereby affecting downstream signaling events. Since ZNF354B is a transcription factor that could be regulated by signaling cascades involving ERK, its activity is functionally inhibited by such disruption. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can lead to reduced protein synthesis and indirectly inhibit ZNF354B by affecting the cellular growth signals which could regulate the transcriptional environment and availability of co-factors for ZNF354B. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that changes the chromatin structure and thereby modulates gene expression. ZNF354B, as a transcription factor, is sensitive to changes in chromatin structure and thus its ability to bind DNA and regulate gene expression could be indirectly inhibited. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor which leads to hypomethylation of DNA and alters gene expression. As ZNF354B's activity is dependent on the transcriptional machinery, interference in DNA methylation can indirectly inhibit its functional activity by changing the expression patterns of genes that ZNF354B may regulate. | ||||||